Hans Biomed Corp

As of March 31, 2026, Hans Biomed Corp carries a market capitalization of 480.61B, placing it among publicly traded companies globally. Its enterprise value stands at 504.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hans Biomed Corp's next confirmed earnings release is scheduled for December 17, 2026.

As of March 31, 2026, Hans Biomed Corp has 14.26M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 4.09, and the price-to-book ratio stands at 6.48.

These figures are as of March 31, 2026. The EV/Sales ratio of 4.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 504.64B versus a market cap of 480.61B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Hans Biomed Corp maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.08, indicating elevated leverage, while an interest coverage ratio of -8.70 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Hans Biomed Corp posted a negative return on equity (ROE) of -35.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.97, reflecting losses generated across the asset base. The company generates approximately 396.77M in revenue per employee across its workforce of 278.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.56 indicates how many times Hans Biomed Corp sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Hans Biomed Corp recorded 2.31B in income tax expense. The company reported a pretax loss of -23.39B and -24.85B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Hans Biomed Corp's stock has declined approximately 46.86% over the past 52 weeks. The 50-day moving average sits at 19,860.20, while the 200-day moving average is 28,393.00.

Over the twelve months ended March 31, 2026, Hans Biomed Corp generated 110.50B in revenue and converted that into -24.85B in net income, yielding earnings per share of -1,917.53. EBITDA reached -15.67B, while operating income came in at -20.41B.

As of March 31, 2026, Hans Biomed Corp holds 17.95B in cash and equivalents against 42.23B in total debt, resulting in a net debt position of 22.35B. Total book value stands at 74.21B, with working capital of 15.14B providing operational flexibility.

Hans Biomed Corp produced -20.21B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2.44B in capital expenditures, free cash flow totaled -22.66B - equivalent to -1,690.08 per share.

Over the twelve months ended March 31, 2026, Hans Biomed Corp posted a gross margin of 59.16, reflecting its pricing power and cost economics. The operating margin of -18.47 and net profit margin of -22.49 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -5.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.10, meaning Hans Biomed Corp raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Hans Biomed Corp has an Altman Z-Score of 3.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.